Share:
ResearchAndMarkets.com s offering.
The Global Companion Diagnostics Market size was valued at USD 1.96 billion in 2019 and is predicted to reach USD 9.02 billion by 2030, with a CAGR of 14.8% from 2020-2030.
Companion Diagnostic (CDx) is a clinical test co-developed with a therapeutic drug for screening the responders and non-responders to that particular drug. It is done in order to identify a patient group that can or cannot be treated with that corresponding drug. CDx helps practitioners to determine the benefits, side effects, and risks associated with the intake of therapeutic drugs, thereby ensuring patient s safety.
Market Dynamics and Trends:
The increasing preferences for targeted therapies, growing applications of personalized medicines, higher prevalence of chronic diseases, and increasing incidences of allergies in patients due to side effects of medicines; give rise to development of customized CDx, thereby propagating the growth of global Companion Diagnost
Global Companion Diagnostics Market Opportunity Analysis and Industry Forecast Report 2021 apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Thermo Fisher Scientific to Host “Oncomine World 2021” Virtual Event, April 29, 2021
Share Article
Don’t miss the opportunity to hear from pathology labs on important topics like hot and emerging biomarker testing, genomic instability, and more
Thermo Fisher Scientific to Host “Oncomine World 2021” Virtual Event. April 29, 2021. WALTHAM, Mass. (PRWEB) April 06, 2021
Thermo Fisher Scientific to hold “Oncomine World 2021” virtually on April 29th, 2021, on the LabRoots platform. It is a chance to learn about the Ion Torrent Genexus NGS System in solid and hematologic tumor clinical research. Dozens of on-demand educational presentations from our 2020 meetings Demonstrations of the Ion Torrent Genexus System, recorded from a Thermo Fisher Scientific lab
Next Generation Sequencing Market Size Worth $11.7 Billion By 2028: Grand View Research, Inc. to reach USD 11.7 billion by 2028 registering a
CAGR of 14.4%, according to a new report by Grand View Research, Inc. As researchers are continuously unlocking the genetic diversity, the development of targeted therapies is on the rise. These therapies are targeted towards narrow populations of patients that have specific or rare genomic biomarkers. Therefore, this is expected to increase the utilization of next generation sequencing (NGS) technology for targeted therapies.
Key suggestions from the report:
The oncology application segment accounted for the largest revenue share in 2020 and will retain its dominance throughout the forecast period due to the development and launch of targeted gene panels for oncology
Next Generation Sequencing Market Size Worth $11 7 Billion By 2028: Grand View Research, Inc prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.